相关实验视频
Updated: Jan 8, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
869
2型糖尿病缓解:多维药理策略和未来前景
Yang Liu1, Xiaokun Gang1, Xinming Liu1
1Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China.
Frontiers in endocrinology
|December 22, 2025
概括
药理学策略,包括胰岛素和新型双重激动剂,对2型糖尿病 (T2DM) 缓解有希望. 组合疗法提高了缓解率和持续时间,将重点从血糖控制转移到疾病缓解.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 2型糖尿病 (T2DM) 是一个具有严重并发症的全球健康挑战.
- 了解T2DM病理生理学对于开发以缓解为重点的药理学策略至关重要.
- 目前存在关于T2DM缓解疗法的疗效,患者选择和长期结果的知识差距.
研究的目的:
- 探索T2DM缓解的各种药物的作用机制和临床影响.
- 分析组合疗法的协同效应,以改善T2DM缓解.
- 提供基于证据的策略,将T2DM缓解从理论转向临床实践.
主要方法:
- 构建了一个整合"机制-药物战略"的分析框架.
- 审查了胰岛素,甲胺,SGLT2抑制剂和GLP-1受体激活剂的临床效应.
- 分析了组合疗法,包括胰岛素,口服药物和多目标口服药物.
主要成果:
- 短期强化胰岛素治疗改善了β细胞功能和胰岛素敏感性,导致一些患者持续缓解.
- 新型双GLP-1/GIP激动剂提供显著的血糖控制和减肥益处.
- 结合疗法,如胰岛素与口服药物或多目标口服药物,改善了缓解率和持续时间.
- 非抗高血糖药物,如维生素D和性激素,显示出糖尿病缓解的潜力.
结论:
- 药理干预为T2DM缓解提供了多维进展.
- 优化治疗计划和组合策略可以提高缓解率并减少药物负担.
- 长效组合和预测模型的未来研究可能会将T2DM管理转向疾病缓解.
相关概念视频
Diabetes: Management and Pharmacotherapy
844
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
844
Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Carbohydrate Metabolism
13.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.7K
Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K

